Inside Stayble: January 2021
In the January 2021 edition, CEO Andreas Gerward, gives a status report from the ongoing Phase 2b trial, current partnering activities and the upcoming rights issue.
Inside Stayble is a communication channel aiming to provide shareholders with monthly updates about Stayble Therapeutics and its clinical development program for STA363 in chronic low back pain.
Stayble Therapeutics is listed on Nasdaq First North in Sweden (STABL).
Read more at staybletherapeutics.com